Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hemispherx Biopharma (HEB)

Hemispherx Biopharma (HEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Hemispherx Biopharma 2117 SW HIGHWAY 484 OCALA FL 34473 USA

www.hemispherx.net P: 215-988-0080

Description:

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.

Key Statistics

Overview:

Market Capitalization, $K 4,396
Shares Outstanding, K 2,442
Annual Sales, $ 370 K
Annual Net Income, $ -9,810 K
Last Quarter Sales, $ 30 K
Last Quarter Net Income, $ -2,030 K
60-Month Beta 0.80
% of Insider Shareholders 11.00%
% of Institutional Shareholders 1.40%
Float, K 2,173
% Float 89.00%

Growth:

1-Year Return -84.85%
3-Year Return -97.12%
5-Year Return -98.78%
5-Year Revenue Growth 146.67%
5-Year Earnings Growth 81.68%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 08/21/19
Earnings Per Share ttm -8.55
EPS Growth vs. Prev Qtr 65.30%
EPS Growth vs. Prev Year 51.42%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-44 on 06/11/19

HEB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -219.87%
Return-on-Assets % -68.60%
Profit Margin % -2,651.35%
Debt/Equity 0.45
Price/Sales 12.04
Price/Cash Flow N/A
Price/Book 0.75
Book Value/Share 2.95
Interest Coverage -18.62
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar